Gastroesophageal Reflux Disease Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Gastroesophageal Reflux Disease Market is Segmented by Product (Diagnosis, and Drug Type) and Geography

Market Snapshot

Gastroesophageal Reflux Disease Market Size
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.3 %
Gastroesophageal Reflux Disease Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The major factors for the growth of the gastroesophageal reflux disease market includes the rising prevalence of gastroesophageal reflux diseases and changing lifestyle, and increasing awareness about GERD.

According to the World Health Organization, in 2017, globally there are more than USD 10 billion that was found to be spent every year on antacids. As per the World Gastroenterology Organization, the prevalence rate of GERD is growing rapidly across the world. It was valued at approximately 2.5%-6.6% in South East Asia and almost 13.8%-25.8% in North America. In geriatric population, acidic complications are recurrent, which provides a unique challenge, for both, the primary care providers and gastroenterologists. Thus, rising cases of GERD the market is expected to witness high demand.

In addition, the growing number of companies for the treatment of acid reflux disorders is majorly attributable for the increase in the market.

Scope of the Report

As per the scope of this report, gastroesophageal reflux is a disorder in which the lower esophageal sphincter is affected, and causes the backflow of contents from stomach to esophagus. Lower esophageal sphincter is a ring of muscles, between the esophagus and the stomach. The symptoms of gastroesophageal reflux disease include frequent chest pain, difficulty swallowing, sensation of lump in the throat etc. The major causes of gastroesophageal reflux disease include obesity, smoking and high adoption rate of poor lifestyle habits.

By Product
Upper Endoscopy
Ambulatory Acid (pH) Probe Test
Esophageal Manometry
Drug Type
Proton Pump Inhibitors (PPIs)
H2 Receptor Blockers
North America
United States
United Kingdom
Rest of Europe
Asia Pacific
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Proton Pump Inhibitors Segment is Expected to hold the Large Market Share over the Forecast Period

  • Proton pump inhibitors accounted for the second largest segment as they are the most commonly prescribed medication for the treatment of acid reflux. The Proton Pump Inhibitors (PPI) characterize the maximum potency in inhibiting gastric acid secretion, primarily by blocking the acid pump. These inhibitors are well-known, for both, therapeutic effects and good safety profiles. 
  • Heartburn and regurgitation are the most common acid reflux-related symptoms in Canadian patients, and many individuals self-diagnose and self-treat these symptoms. PPIs are the most successful short-term treatment for recurrent or severe heartburns. The OTC status of some PPI drugs is expected to augment their sales. Thus, owing to the all above mentioned factors the market is expected to witness a high growth.
Gastroesophageal Reflux Disease Market Trends

North America is Expected to Hold the Largest Market Share over the Forecast Period

The United States is expected to be the largest market owing to the presence of better healthcare infrastructure and the rising prevalence of GERD. In the United States, tablet (chewable form) and liquid forms are most widely used. There is a rising prevalence of GERD across the world, although there are marked differences in the reported prevalence, ranging from 14% to 26% in North America. 

However, it can be correlated with the rising prevalence of obesity, along with other dietary factors, in many countries. GERD can be associated with the impact on the quality of life and reduction in personal and work-related productivity. In the United States, major selling drugs include omeprazole, Pantoprazole Sodium, and Nexium. Thus, owing to the lifestyle change and rising cases of GERD the market is expected to grow.

On the other hand, the Asia Pacific region is also being projected to showcase the fastest growth rate over the forecast period due to the rising geriatric population.

Gastroesophageal Reflux Disease Market Growth

Competitive Landscape

The market studied is a fragmented market owing to the presence of various market players. Some of the market players are  GlaxoSmithKline PLC, Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Medtronic Plc, Olympus Corporation, Pfizer, Inc., Reckitt Benckiser Group PLC, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceuticals Industries Limited.

Table of Contents


    1. 1.1 Study Deliverables

      1. 1.1.1

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Gastrointestinal Reflux Diseases and Changing Lifestyle

      2. 4.2.2 Increasing Awareness about GERD

    3. 4.3 Market Restraints

      1. 4.3.1 Patent Expiry of Blockbuster Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product

      1. 5.1.1 Diagnosis

        1. Upper Endoscopy

        2. Ambulatory Acid (pH) Probe Test

        3. Esophageal Manometry

        4. Others

      2. 5.1.2 Drug Type

        1. Proton Pump Inhibitors (PPIs)

        2. H2 Receptor Blockers

        3. Others


    2. 5.2 Geography

      1. 5.2.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.2.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.2.3 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.2.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.2.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 GlaxoSmithKline PLC

      2. 6.1.2 SRS Life Sciences

      3. 6.1.3 Johnson & Johnson

      4. 6.1.4 Medtronic Plc

      5. 6.1.5 Pfizer, Inc.

      6. 6.1.6 Reckitt Benckiser Group Plc

      7. 6.1.7 Takeda Pharmaceutical Co., Ltd.

      8. 6.1.8 Teva Pharmaceuticals Industries Limited.

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Gastroesophageal Reflux Disease Market market is studied from 2018 - 2026.

The Gastroesophageal Reflux Disease Market is growing at a CAGR of 4.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

GlaxoSmithKline PLC, Pfizer, Inc., Johnson & Johnson, SRS Life Sciences, Takeda Pharmaceutical Co., Ltd. are the major companies operating in Gastroesophageal Reflux Disease Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!